Search

Displaying results 2331 - 2340 of 4438 in total
  1. Drug

    Anthoxanthum odoratum

    go.drugbank.com/drugs/DB14163
    Approved

    Anthoxanthum odoratum allergenic extract is used in allergenic testing.

  2. Drug

    CX-051869

    go.drugbank.com/drugs/DB31656
    Approved

    CX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1. It is the active ingredient of the 2025-2026 formulation of Moderna's Spikevax vaccine.

  3. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. … APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation.

  4. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.

  5. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group.

  6. Drug

    Chlormerodrin

    go.drugbank.com/drugs/DB00534
    ApprovedWithdrawn

    Chlormerodrin is a mercurial compound with toxic side effects that was previously used as a diuretic. The radiolabeled form has been used as a diagnostic and research tool. It is no longer used and has been replaced with new classes of d...

  7. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label].

  8. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

  9. Drug

    Futibatinib

    go.drugbank.com/drugs/DB15149
    ApprovedInvestigational

    [A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.

  10. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985]